CAMBRIDGE, Mass.--(BUSINESS WIRE)--Xanthus Pharmaceuticals, Inc. today announced the presentation of initial results from the Company’s Phase 2 study of Xanafide® in patients with secondary acute myeloid leukemia (AML). The presentation was made by Dr. Harry P. Erba, M.D., Ph.D., Associate Professor of Internal Medicine at the University of Michigan Health System, at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). In the Phase 2 trial, treatment with Xanafide and ara-C was associated with a favorable complete remission rate and an acceptable safety profile.
